Abstract: The disclosure relates to 1,2-substituted ergoline derivatives of general Formula I ##STR1## wherein X is an oxygen or sulfur atom,R.sup.1 is a lower alkyl group,R.sup.2 is halogen, acyl, a saturated or unsaturated lower alkyl group which can optionally be substituted by OR.sup.4 wherein R.sup.4 is hydrogen, lower alkyl, tetrahydropyranyl or cycloalkyl, or by an optionally substituted aryl residue, an S-R.sup.5 -group wherein R.sup.5 means a lower alkyl group which can optionally be substituted by aryl or an optionally substituted aryl residue, a ##STR2## wherein n=2 o4 3, or a --CHO-group, R.sup.3 is lower alkyl or acyl, andC.sub.9 -C.sub.10 is a CC-single or a CC-double bond, and the hydrogen atom in the 10-position is in the .alpha.-location if C.sub.9 -C.sub.10 is a CC-single bond, as well as the acid addition salts thereof. The compounds exhibit valuable pharmacological properties.

Abstract: Novel 12- and 13-substituted ergoline derivatives are suitable, e.g., as psychopharmaceuticals and for hypertension therapy.

Abstract: An ergoline derivative of the formula I: ##STR1## wherein R.sub.1 represents hydrogen or a methyl group; R.sub.2 represents hydrogen or a halogen atom, a methyl, cyano or phenyl group or an alkylthio group having from 1 to about 4 carbon atoms; R.sub.3 represents a hydrocarbon group having from 1 to about 4 carbon atoms; R.sub.4 represents hydrogen, a phenyl group or a hydrocarbon group having from 1 to about 4 carbon atoms; wherein either (a) R.sub.6 and R.sub.7 represent a valence bond or hydrogen atoms and R.sub.8 represents a hydrogen atom or a methoxy group, or (b) R.sub.6 represents a hydrogen atom and R.sub.7 and R.sub.8 taken together represent a valence bond; W represents an oxygen atom or an imino group; A represents a group of the formula CHR.sub.5, CH.dbd.CR.sub.5 or CH.sub.2 CHR.sub.5 wherein R.sub.

Abstract: Compounds of general Formula I labeled with .sup.121 I, .sup.122 I, .sup.123 I, .sup.124 I, .sup.125 I, .sup.131 I and .sup.132 I isotopes ##STR1## wherein R.sup.6 is a C.sub.1-6 aliphatic hydrocarbon residue andC.sub.2 -C.sub.3 C.sub.9 -C.sub.10 is a single or a double bond, as well as their acid addition salts,are useful as diagnostic media, e.g., in imaging dopamine and other receptors.

Abstract: (2-Haloergolinyl)-N',N'-diethylurea derivatives of Formula I ##STR1## and the salts thereof, wherein R is hydrogen, alkyl of up to 6 carbon atoms, or alkenyl of up to 3 carbon atoms,X is halogen, ##STR2## is a CC single or CC double bond, and the urea residue in the 8-position can be in the .alpha.- or .beta.-configuration, have neuropsychotropic properties.As a result, they are excellently suitable for treatment of psychotic disturbances and emesis.

Abstract: Novel ergoline derivatives, substituted in the 2-position, of the formula ##STR1## wherein C.sub.8 ---C.sub.9 and C.sub.9 ---C.sub.10 each independently is a CC-single or a C.dbd.C-double bond, but not together a cumulated double bond, and the substituent in the 8-position is in the .alpha.- or .beta.-configuration where C.sub.8 ---C.sub.9 is a CC-single bond,R.sup.2 is a CN, SR, SOR, ##STR2## wherein n is 2 or 3, ##STR3## and --CH(OR)R whereinR has the meaning of H or C.sub.1-4 -alkyl,the grouping COR' and CSR'wherein R'=OH, OC.sub.1-4 -alkyl, benzyl, NH.sub.2 or NHR",the grouping CH.dbd.CH--CO.sub.2 R" and CH.sub.2 --CH.sub.2 --CO.sub.2 R'wherein R"=C.sub.1-4 -alkyl,the grouping C.tbd.C--R'" and HC.dbd.CH--R'"wherein R'"=hydrogen, C.sub.1-4 -alkyl, phenyl, CH.sub.2 OH, CR".sub.2 OH, ##STR4## CO.sub.2 R", CH.sub.2 NR".sub.2 or SiMe.sub.2 R"; C.sub.1-3 -alkyl, or C.sub.1-3 -alkyl substituted by OH or phenyl; or ##STR5## wherein R" is C.sub.1-4 alkyl, R.sup.6 is C.sub.1-4 -alkyl andR.sup.

Abstract: There are disclosed intermediates to pharmaceutical compounds of the formula ##STR1## in which R.sup.1 is an aliphatic or aromatic function, and R.sup.2 and R.sup.3 are each hydrogen, C.sub.1-4 alkyl or a protecting group; and salts thereof.

Abstract: Novel 2-substituted ergolinyl urea and thioruea derivatives are disclosed, as well as their use as pharmaceuticals, specifically as neuroleptics. The compounds, which possess central dopaminergic activity, have the formula ##STR1## wherein X is an oxygen or sulfur atom,R.sup.1 is a lower alkyl group,Y is a sulfur atom, S--CH.sub.2 --, C.sub.2 H.sub.4 --, --CH.dbd.CH--, or --C.tbd.C--,R.sup.2 is an aromatic ring of 5-6 atoms, 0-3 of which are O, S or N; or an aromatic ring of 5-6 atoms, 0-3 of which are O, S or N, and which is substituted by C.sub.1-2 -alkyl, C.sub.1-2 -alkoxy, nitrile, nitro, amino, C.sub.1-2 -alkylamino, carbonylamino or halo group, andC.sub.9 C.sub.10 is a CC-single or a CC-double bond and, if C.sub.9 C.sub.10 means a CC-single bond, the hydrogen atom in the 10-position is in the .alpha.-location,or a pharmaceutically acceptable acid addition salt thereof, wherein, if X is an oxygen atom, R.sup.1 is methyl and C.sub.9 C.sub.10 is a single bond, Y--R.sup.2 does not mean --C.sub.2 H.sub.

Abstract: Ergolinyl compounds which are nitrogen-substituted in the 8-position and have Formula (I) ##STR1## and physiologically compatible salts thereof, wherein (a) R.sup.1 is hydrogen, the 8-substituent can be in the .alpha.- or .beta.-position and ##STR2## represents a single or a double bond, R.sup.2 is hydrogen, C.sub.1-4 -alkyl or C.sub.1-7 -acyl,R.sup.3 is hydrogen, chlorine or bromine, andR.sup.4 is C.sub.1-6 -alkyl, C.sub.3-6 -cycloalkyl-C.sub.1-3 -alkyl, C.sub.3-6 -alkenyl, or C.sub.3-6 -alkynyl; or(b) R.sup.1 is ##STR3## and the 8-substituent can be in the .alpha.- or .beta.-position, ##STR4## represents a single or double bond, R.sup.2, R.sup.3 are as defined above,R.sup.4, is C.sub.1.varies.6 -alkyl, C.sub.3-6 -cycloalkyl-C.sub.1-3 -alkyl, C.sub.3-6 -alkenyl, or C.sub.3-6 -alkynyl; andR.sup.5 is hydrogen, C.sub.-10 -alkyl, C.sub.3-10 -alkenyl, or C.sub.3-10 -alkynyl, andR.sup.6 is C.sub.1-10 -alkyl, C.sub.3-10 -alkenyl, C.sub.3-10 -alkynyl, or aryl, orR.sup.5 and R.sup.

Abstract: The invention relates to a novel process for the halogenation in 2-position of ergot alkaloids. The process is characterized by that as a halogenating agent a system consisting of dimethylsulfoxide, a trialkylhalosilane or triarylhalosilane and optionally a hydrogen halide is used.

Abstract: Ergolinylthioureas derivatives of the general Formula I ##STR1## wherein R.sup.1 is hydrogen, lower alkyl or acyl,R.sup.2 is hydrogen, halogen or a lower alkylthio groupR.sup.3 is lower alkyl,R.sup.4, R.sup.5 and R.sup.6, is hydrogen or lower alkyl, and each is identical or different,n=0, 1 or 2 and C.sub.9 --C.sub.10 is a single or a double bond; are produced by reacting in an ergolin-8-ylurea compound otherwise corresponding to Formula I with a --CO--NR.sup.5 R.sup.6 group in place of the --CS--Nr.sup.5 R.sup.6 group is reacted with a chlorinating agent and a thiolating agent.

Abstract: The present invention provides N,N-Diethyl-N'-[(8.alpha.)-1-ethyl-6-methyl-ergolin-8-yl]-sulfamide, and N,N-Diethyl-N'-[(8.alpha.)-1-isopropyl-6-methyl-ergolin-8-yl)-sulfamide useful as prolactin secretion inhibiton, anti-parkinson agents and anti-depressant agents.

Abstract: Compounds of formula I ##STR1## wherein R.sub.1 is hydrogen or C.sub.1-4 alkyl, R.sub.2 is hydrogen, chlorine, bromine or methyl, R.sub.3 is C.sub.1-5 alkyl or C.sub.3-5 alkenyl and R.sub.4 is C.sub.1-7 alkyl; C.sub.3-7 cycloalkyl; adamantyl; or optionally substituted phenyl, are useful as neuroleptic agents and PRL secretion inhibitors.

Abstract: Ketoalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)ergoline-8.beta.-carboxylic acid, useful and 5HT receptor antagonists.

Abstract: Novel 1-alkyl ergolinylthiourea derivatives of the general formula ##STR1## wherein R.sup.1 is C.sub.1-6 alkyl,R.sup.2 and R.sup.3 are C.sub.1-4 alkyl,R.sup.4 is hydrogen or C.sub.1-4 alkyl andC.sub.9---- C.sub.10 is a single bond or a double bond,and the acid addition salts thereof, with the provision that when R.sup.3 and R.sup.4 are both ethyl, R.sup.1 and R.sup.2 are not methyl and acid addition salts thereof are provided; as well as a process for the preparation of these compounds. The compounds are useful as medicinal agents, e.g., for the treatment of mental depression.

Abstract: Substituted ergolines of the formula ##STR1## and their acid addition salts, wherein the urea side chain in the 8-position can be in the d.alpha.- or .beta.-configuration, C.sub.2 C.sub.3 and C.sub.9 C.sub.10 are a CC single or C.dbd.C double bond, andR is hydrogen or NR'R" wherein R'R" is O.sub.2, H.sub.2, C.sub.1-4 -dialkyl, or, together, they form a 3- to 9-membered ring, or R' and R" individually are hydrogen, C.sub.1-4 -alkyl, or C.sub.1-10- -acyl,R.sup.1 is hydrogen, C.sub.1-4 -alkyl, C.sub.1-10 -acyl, C.sub.6-8 -aryl, or C.sub.1-4 -alkylsulfonyl,R.sup.2 is hydrogen or halogen if C.sub.2 C.sub.3 is a C.dbd.C double bond, or hydrogen if C.sub.2 C.sub.3 is a CC single bond,R.sup.6 is C.sub.1-4 -alkyl,show a pronounced effect on the central nervous system and are suitable, for example, as antidepressants, neuroleptics, or antihypertensives.

Abstract: A compound of formula I ##STR1## wherein R.sub.1 is n-propyl,R.sub.2 is hydrogen or alkyl(C.sub.1-3),R.sub.3 is alkyl(C.sub.1-3), andR.sub.4 is hydrogen or methylin free base form or in pharmaceutically acceptable acid addition salt form is useful as a prolactin secretion inhibitor, anti-parkinson and anti-depressant agent.

Abstract: The invention relates to a novel process for the preparation of partially new 2-halonicergoline derivatives of the formula (I), ##STR1## wherein X stands for chlorine, bromine or iodine atom, as well as their acid addition salts.The process of the invention comprises esterifying a novel 2-halo-1-methyllumilysergol of the formula (II), ##STR2## wherein X is the same as defined above, or an acid addition salt thereof and, if desired, converting the thus-obtained 2-halonicergoline derivative of the formula (I) to an acid addition salt.The compounds of the invention improve the cognitive function of the brain and show an antihypoxic as well as a strong .alpha.-adrenerg blocking and calcium-antagonistic action.

Abstract: A process for preparing an N-methyl derivative of ergoline of formula: ##STR1## in which R.sub.1 denotes a carboxy or alkoxycarbonyl group in which the alkyl portion contains 1 to 4 carbon atoms, R.sub.2 denotes a hydrogen atom or a methoxy group and R.sub.3 denotes a hydrogen atom or R.sub.2 and R.sub.3 together form a direct bond, or in which R.sub.1 denotes a hydroxymethyl group, R.sub.2 denotes a hydrogen atom or a methoxy group and R.sub.3 denotes a hydrogen atom, which comprises methylating an ergoline derivative of formula: ##STR2## in which R.sub.1, R.sub.2 and R.sub.3 are defined as above, with methyl carbonate in the presence of a basic agent, in an apolar aprotic solvent in the present of a phase transfer catalyst.

Abstract: A process for preparing an ergoline of the formula ##STR1## wherein C.sub.9 ----C.sub.10 is a CC single or double bond,R.sup.1 is hydrogen or CONR.sub.2, R being hydrogen, methyl, or ethyl, and wherein NR' is in the .alpha.- or .beta.- position,R.sup.2 is lower alkyl of up to 3 carbon atoms, and the salts thereof,comprises treating the corresponding ergolinyl carboxylic acid amide with lead(IV) acetate in an aprotic polar solvent; reacting the intermediarily formed corresponding isocyanate with water or with a reactive amine of up to 4 carbon atoms, (e.g. a mono- or dialkylamine of up to 4-C atoms); and, optionally, treating the resultant product with an acid to form the corresponding salt.

Abstract: Ergoline derivatives of the formula I ##STR1## wherein R.sub.1 =H,CH.sub.3 ; R.sub.2 =H, halogen, CH.sub.3, CN, C.sub.1 -C.sub.4 alkylthio or phenylthio; R.sub.3 =C.sub.1 -C.sub.4 hydrocarbon; R.sub.4 =H, OCH.sub.3 ; R.sub.5 =H and R.sub.6 =--CH.dbd.CH--CONHR.sub.7 or R.sub.5 and R.sub.6 =.dbd.CH--CONHR.sub.7 ; R.sub.7 =2-thiazolyl, 3-pyridazinyl, 1,3,4-thiadiazol-2-yl or 4-pyrimidinyl group optionally substituted, and pharmaceutically acceptable salts thereof, display activity on the Central Nervous System and are useful as antiprolactinic agents. Their preparation and pharmaceutical compositions containing them are also described.

Abstract: There are disclosed pharmaceutical compounds of the formula ##STR1## in which R.sup.1 is an aliphatic or aromatic function, and R.sup.2 and R.sup.3 are each hydrogen, C.sub.1-4 alkyl or a protecting group; and salts thereof.

Abstract: Novel 12- and 13-bromoergoine derivatives are suitable as medicines for treating psychic disorders of the depressive array of symptoms and also as intermediates.

Abstract: The present invention provides a process for N-alkylating dihydrolysergic acid with a substituted benzenesulfonate derivative.

Abstract: Novel ergoline derivatives, substituted in the 2-position, of the formula ##STR1## wherein C.sub.8 -C.sub.9 and C.sub.9 -C.sub.10 each independently is a CC-single or a C.dbd.C-double bond, but not together a cumulated double bond, and the substituent in the 8-position is in the .alpha.- or .beta.-configuration where C.sub.8 -C.sub.9 is a CC-single bond,R.sup.2 isCN, SR, SOR, ##STR2## wherein n is 2 or 3, ##STR3## and --CH(OH)R, wherein R has the meaning of H or C.sub.1-4 -alkyl, the grouping COR' and CSR' wherein R'.dbd.OH, OC.sub.1-4 -alkyl, benzyl, NH.sub.2 or NHR",the grouping CH.dbd.CH--CO.sub.2 R" and CH.sub.2 --CH.sub.2 --CO.sub.2 R" wherein R".dbd.C.sub.1-4 -alkyl,the grouping C.vertline.C-R'" and HC.dbd.CH--R'" wherein R'".dbd. hydrogen, C.sub.1-4 -alkyl, phenyl, CH.sub.2 OH, CR".sub.2 OH, ##STR4## CO.sub.2 R", CH.sub.2 NR".sub.2 or SiMe.sub.2 R"; C.sub.1-3 -alkyl, or C.sub.1-3 -alkyl substituted by OH or phenyl; or ##STR5## wherein R" is C.sub.1-4 alkyl, R.sup.6 is C.sub.1-4 -alkyl andR.sup.

Abstract: Cyclic ether esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)ergoline-8.beta.-carboxylic acid, useful as 5HT receptor antagonists.

Abstract: Phenacyl or substituted phenacyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)ergoline-8.beta.-carboxylic acid, useful as 5HT receptor antagonists.

Abstract: The invention relates to a novel process for the preparation of 2-bromo-.alpha.-ergocryptine and its acid addition salt by brominating .alpha.-ergocryptine in such a way that the bromination is carried out at room temperature by using a dimethylsulphoxide-hydrogen bromide mixture containing no more 0.02% of water and, if desired, converting the thus-obtained 2-bromo-.alpha.-ergocryptine to an acid addition salt in a known manner.

Abstract: 2-bromoergolines can be reduced in good yields, without dimerization as determined by NMR product analysis, to the corresponding 2,3-dihydroergolines under otherwise conventional reducing conditions by introducing 2-bromoergolines, together with sodium borohydride, into trifluoroacetic acid under cooling to prevent the reaction mixture from rising above ambient temperature.

Abstract: Compounds of formula I: ##STR1## wherein R.sub.1 represents a hydrogen atom or a methyl group; R.sub.2 represents a hydrogen or halogen atom or a methyl, cyano, C.sub.1 -C.sub.4 alkylthio or phenylthio group; R.sub.7 and R.sub.8 represent hydrogen atoms and R.sub.3 represents a hydrogen atom or a methoxy group, or R.sub.7 represents a hydrogen atom and R.sub.3 and R.sub.8 taken together represent a bond, or R.sub.3 represents a hydrogen atom or a methoxy group and R.sub.7 and R.sub.8 taken together represent a bond; R.sub.4 represents a hydrocarbon group having from 1 to 4 carbon atoms; R.sub.5 represents a hydrogen atom or a hydrocarbon group having from 1 to 4 carbon atoms or a phenyl group; X represents an oxygen or sulphur atom or an imino group, R.sub.9 represents a hydrogen atom and B represents a cyano, a C.sub.2 -C.sub.5 alkoxycarbonyl or carbamoyl group, or R.sub.

Abstract: Mono, difluoro or trifluoroalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)-ergoline-8.beta.-carboxylic acid, useful as 5HT.sub.2 receptor antagonists.

Abstract: Cycloalkyl or ketocycloalkyl esters of 1-substituted-6-C.sub.1-4 straight chain alkyl (or allyl)-ergoline-8.beta.-carboxylic acids, useful as 5HT.sub.2 receptor antagonists.

Abstract: The invention concerns a process for the isomerization of ergoline derivatives substituted in the 8.beta. position by an electron withdrawing radical to the corresponding 8.alpha. compounds by removal of the proton in the 8.alpha. position and by a following, separately effected, protonation.

Abstract: There are provided ergoline derivatives of formula ##STR1## wherein R.sub.1 .dbd.H, CH.sub.3 ; R.sub.2 .dbd.H or halogen atom, or CH.sub.3,CN, alkyl- or phenyl-thio; R.sub.3 .dbd.H, OCH.sub.3 ; R.sub.4 .dbd.C.sub.1 -C.sub.4 hydrocarbon group; X.dbd.O, S, NH; A.dbd.CO, SO.sub.2 ; B.dbd.C.sub.1 -C.sub.4 hydrocarbon group, aryl, aralkyl, heterocyclic ring group, alkoxy, aryloxy; n.dbd.0, 1, 2; and pharmaceutically acceptable salts thereof.A process for preparing said compounds is also provided. The compounds show anti-hypertensive activity and are active on the gastroenteric system.

Abstract: A process for the production of an ergot alkaloid comprising intramolecularly cyclizing a 3-iminoethyl-4-trans-buta-1',3'-dienylindole to produce an 8-ergolene and as necessary converting the resultant ergolene into the desired ergot alkaloid.

Abstract: A process for preparing an 8.alpha.-substituted 6-methyl-10.alpha.-H-ergoline of the formula ##STR1## wherein R.sub.1 is HN--CO--NX.sub.2 (wherein X is hydrogen, methyl or ethyl), CO--NH--NX.sub.2, CO--NX.sub.2, or CH.sub.2 OX, comprises reducing the corresponding 8.alpha.-substituted-9,10-didehydro-6-methylergoline, with an alkali metal or alkaline earth metal dissolved in a nitrogen compound which is a primary or secondary C.sub.1-3 -alkylamine, a hexa-C.sub.1-2 -alkyl-phosphoric triamide or ammonia at a temperature of -70.degree. to -30.degree. C.

Abstract: Soluble polymeric colorants composed of free amine groups and chromophoric groups covalently bonded to an organic backbone are disclosed. The number of free amine groups is not less than one-half the number of chromophoric groups. The colorants are characterized by being free of sulfonate, phosphonate and carboxylate groups. The preparation and use of these colorants is also disclosed.

Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is alkyl of 2-6 carbon atoms, ##STR2## n is 1, or 2, m is 0 or 1,R.sub.2 is alkyl of 1-6 carbon atoms, ##STR3## is a CC single bond or a CC double bond, and the 8-positioned urea residue can be in the .alpha.- or .beta.-position, have valuable pharmacological properties, e.g., lactation inhibition and anti-Parkinsonism.

Abstract: The present invention provides compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,R.sub.1 is methyl or ethyl,R.sub.2 is alkyl of 1 to 4 carbon atoms or allyl,R.sub.3 is CH.sub.2 CN or a group --NR.sub.4 R.sub.5, wherein R.sub.4 is hydrogen or alkyl of 1 to 4 carbon atoms, and R.sub.5 is alkanoyl of 1 to 5 carbon atoms, alkoxycarbonyl of 2 to 5 carbon atoms in the aggregate thereof, or mono-, di- or tri-haloalkoxycarbonyl of 3 to 5 carbon atoms, wherein the alkoxy group is substituted by halogen other than in the .alpha. position to the oxygen atom, or R.sub.5 is SO.sub.2 R.sub.6, wherein R.sub.6 is alkyl of 1 to 4 carbon atoms, mono-, di- or tri-haloalkyl of 1 to 4 carbon atoms, phenyl, phenyl mono-substituted by halogen or alkoxy of 1 to 4 carbon atoms, or pyridyl, or R.sub.6 is a group NR.sub.7 R.sub.8, wherein R.sub.7 and R.sub.8 are, independently, hydrogen or alkyl of 1 to 4 carbon atoms, or R.sub.7 and R.sub.8 together form --[CH.sub.2 ].sub.n -- or --[CH.sub.2 ].sub.2 --A--[CH.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein X is hydrogen, chlorine or bromine,R.sub.1 is methyl or ethyl, andR.sub.2 is CH.sub.2 --CN, or a group NR.sub.3 R.sub.4, whereinR.sub.3 is hydrogen or alkyl of 1 to 4 carbon atoms, andR.sub.4 is SO.sub.2 R.sub.5, wherein R.sub.5 is alkyl of 1 to 4 carbon atoms, mono- to tri-halogenalkyl of 1 to 4 carbon atoms, phenyl, pyridyl, phenyl monosubstituted by halogen or alkoxy of 1 to 4 carbon atoms, or a group NR.sub.6 R.sub.7, wherein each ofR.sub.6 and R.sub.7 is independently hydrogen or alkyl of 1 to 4 carbon atoms, orR.sub.6 and R.sub.7 together are one of the groups (CH.sub.2).sub.n or (CH.sub.2).sub.2 --A--(CH.sub.2).sub.2, whereinn is a number from 3 to 7, andA is oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms or phenyl,useful as prolactin secretion agents and antiparkinson agents.

Abstract: Compounds and process for making same are disclosed, the compounds having the formula (I): ##STR1## wherein R.sub.1 represents methyl, phenyl, piperidino, 1-pyrrolidinyl, morpholino or 4-methyl-1-piperazinyl, alkyl or alkoxy having from 1 to 4 carbon atoms, amino, substituted amino of the formula NHR' (wherein R' is alkyl having from 1 to 4 carbon atoms, cycloalkyl, a benzyl, or phenyl) or substituted amino of the formula NR" R"' (wherein R" and R"' both represent alkyl having from 1 to 4 carbon atoms);R.sub.2 represents a hydrogen atom, alkyl having from 1 to 4 carbon atoms, or phenyl;R.sub.3 represents a fluorine atom, cyano, difluoromethyl, difluorobromomethyl, trifluoromethyl, methylthio, methylsulphonyl, sulphonamido, an alkoxy having from 1 to 4 carbon atoms, an alkanoyl having from 2 to 5 carbon atoms, or benzoyl;R.sub.4 represents a hydrocarbon having from 1 to 4 carbon atoms;R.sub.5 represents a hydrogen atom or methoxy;R.sub.6 represents a hydrogen or halogen atom or methyl; andR.sub.

Abstract: Novel compositions comprising acetylenic polyhemi-amic acid compositions and processes for their preparation are disclosed herein. These new compositions are primarily derivatives of anhydride-terminated aromatic polyimides from which they are prepared by amidation to provide acetylenic amide groups having terminal .dbd.C.tbd.CH groups as hemi-amic acid groups of their derivatives. These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation thereby extending greatly the applications for which the aromatic polyimides can be employed. Also included are monomeric compounds containing acetylenic amide groups derived from monomeric tetracarboxylic dianhydrides. These are particularly useful as crosslinking agents.

Abstract: Novel compositions comprising unsaturated polyhemi-amic acid compositions and processes for their preparation are disclosed herein. These new compositions are primarily derivatives of anhydride-terminated aromatic polyimides from which they are prepared by amidation to provide unsaturated amide groups having terminal --CH.dbd.CH.sub.2 groups as hemi-amic acid groups or their derivatives. These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation thereby extending greatly the applications for which the aromatic polyimides can be employed. Also included are monomeric compounds containing unsaturated amide groups derived from monomeric tetracarboxylic dianhydrides. These are particularly useful as crosslinking agents.

Abstract: Novel compositions comprising acetylenic polyimide-polyamides and processes for their preparation are disclosed herein. These new compositions are primarily derivatives of anhydride-terminated aromatic polyimides from which they are prepared by amidation to provide acetylenic amide groups having terminal --C.dbd.CH groups. These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation thereby extending greatly the applications for which the aromatic polyimides can be employed. Also included are monomeric compounds containing acetylenic amide groups derived from monomeric tetracarboxylic dianhydrides. These are particularly useful as crosslinking agents.

Abstract: Novel compositions comprising unsaturated polyimide-polyamides and processes for their preparation are disclosed herein. These new compositions are primarily derivatives of anhydride-terminated aromatic polyimides from which they are prepared by amidation to provide unsaturated amide groups having terminal --CH.dbd.CH.sub.2 groups. These new compositions are more tractable than the original anhydride-terminated polyimides and can be converted at appropriate lower temperatures to crosslinked, insoluble, infusible polymers without by-product formation thereby extending greatly the applications for which the aromatic polyimides can be employed. Also included are monomeric compounds containing unsaturated amide groups derived from monomeric tetracarboxylic dianhydrides. These are particularly useful as crosslinking agents.

Abstract: Isoquinoline compounds of the following formula are described: ##STR1## wherein the moiety A-B represents a group of formula:--CH.sub.2 --NR.sup.3 -- or --NR.sup.3 --CH.sub.2 --;wherein R.sup.3 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl, optionally substituted benzyl, C.sub.3-6 alkenyl or C.sub.1-4 alkanoyl;wherein R represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or optionally substituted benzyl;wherein R.sup.1 and R.sup.2 each represent hydrogen or taken together represent a chemical bond; and wherein X is hydrogen or halogen; or an acid-addition salt thereof.The compounds are pharmaceuticals and especially useful in the treatment of disorders of the central nervous system.

Abstract: A process for isolating ergot alkaloids from culture suspensions, in which after mechanical filtration, the residue is dried in a fluidized drying bed and the alkaloids are extracted with an aprotic organic solvent, reextracted with a weakly acidic aqueous solution which is subsequently made basic, and finally extracted with a water-immiscible organic solvent, from which the alkaloids are isolated in a conventional manner. In certain instances, the culture suspension is stirred with an adsorbent clay to entrain the water-soluble alkaloids.

Abstract: A novel process is disclosed for the preparation of derivatives of lysergol having the general formula: ##STR1## According to this process lysergol is directly used as the starting compound and, after the methylation at the 1 position of the corresponding 10 alpha-methoxy-lumilysergol, the methylated compound is directly esterified with a carboxylic acid R--COOH, the acid being selected in the group comprising aliphatic, cycloaliphatic, aromatic, and heterocyclic carboxylic acids, containing up to 10 carbon atoms.

Abstract: Novel compounds of the general formula I ##STR1## wherein M.sup.q.sym. is a metal ion carrying a double or triple positive charge and q is 2 or 3 and r is 1 or 2, the quotient q/r being 1, 1.5, 2 or 3, and L is a piperidine which is substituted by at least one enolate group in the 1-position or 4-position and wherein the ring nitrogen is sterically hindered by alkyl substituents in the adjacent positions, and m is 0, 1 or 2 and A is H.sub.2 O or an amine.

Abstract: Isoquinoline compounds of the following formula are described: ##STR1## wherein the moiety A-B represents a group of formula:--CH.sub.2 --NR.sup.3 -- or --NR.sup.3 --CH.sub.2 --;wherein R.sup.3 represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl, optionally substituted benzyl, C.sub.3-6 alkenyl or C.sub.1-4 alkanoyl;wherein R represents hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, or optionally substituted benzyl;wherein R.sup.1 and R.sup.2 each represent hydrogen or taken together represent a chemical bond; and wherein X is hydrogen or halogen; or an acid-addition salt thereof.The compounds are pharmaceuticals and especially useful in the treatment of disorders of the central nervous system.